Mylan has announced the launch of Repaglinide Tablets, the generic version of Novo Nordisk’s Prandin.
RELATED: Endocrine Disorders Resource Center
Repaglinide is an oral meglitinide used in the management of non-insulin dependent diabetes mellitus (type 2). Repaglinide reduces blood glucose levels by stimulating the release of insulin from the pancreas and closing ATP-dependent potassium channels in the ß-cell membrane through binding at characterizable sites. As the potassium channel blockade depolarizes the ß-cell, the calcium channels are opened and the increased calcium induces insulin secretion.
Mylan’s Repaglinide Tablets are available in 0.5mg, 1mg, and 2mg strengths.
Continue Reading
For more information call (800) RX-MYLAN or visit Mylan.com.
